Oklahoma Blood Institute pioneers ‘donor driven’ blood-based cellular therapies

Published: Tuesday, September 11, 2018 By: Jim Stafford Source: NewsOK

In a room filled with blood donors at the Oklahoma Blood Institute's (OBI) donation center, Jennifer Chain, Ph.D., pronounces some words that don't easily roll off the tongue. Allogeneic. Autologous. Apheresis.

Chain's audience includes me and a pair of colleagues from the Oklahoma Center for the Advancement of Science and Technology (OCAST). We are visiting OBI to learn about its cellular therapy program in which it is developing cell-based products for research and clinical use.

We learn that allogeneic is a blood donation from one person that can be used in different individuals. Autologous is a self-donation from one person for future use by that individual, say, for an upcoming surgery. And apheresis is a process in which a donor's blood components are separated by a centrifuge to collect platelets and plasma.

Along with Chain, Charles Mooney, OBI's vice president for quality management and new business ventures, explains the terminology to us.

Read the full article in The Oklahoman.

Back to top